In conclusion, we propose antagonism of PARP14 with a catalytic inhibitor as a safe and efficacious approach to target high tumour cell intrinsic IFNγ signalling resulting from adaptation to α-PD-1 and thereby restore sensitivity to ICBT in progressing tumours. This evidence concerns the gene PARP14 and neoplasm.